bioAffinity Technologies Secures Mexican Patent Allowance for Lung Cancer Detection Technology
BIAF has more than doubled off its 52-week low of $0.693.
Summary
bioAffinity Technologies announced a patent allowance in Mexico for its CyPath® Lung diagnostic technology, strengthening its global intellectual property protection for early lung cancer detection.
Key Events · Product Development and Regulatory · BIAF
-
Mexican Patent Allowance Received
bioAffinity Technologies received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting lung cancer using flow cytometry.
-
Strengthens CyPath® Lung IP
The patent expands global intellectual property protection for the company's commercially available CyPath® Lung diagnostic test, which utilizes flow cytometry and artificial intelligence for early lung cancer detection.
-
Supports Shareholder Value
Management emphasized that strong intellectual property protection for CyPath® Lung benefits patients, physicians, and supports value creation for shareholders, which is critical given the company's current financial position.
Analysis · BIAF · Industrial Applications And Services
This patent allowance in Mexico strengthens bioAffinity Technologies' intellectual property portfolio for its CyPath® Lung diagnostic test. For a company facing significant financial challenges and a short cash runway, expanding global IP protection for its core commercial product is a positive development that enhances the long-term value of its assets and could support future strategic initiatives or financing efforts.
At the time of this filing, BIAF was trading at $1.74 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.69 to $15.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.